For Moderate to Severe acne, CAB gel turns out to be effective treatment suggests a study published in the Journal of Drugs ...

Dare Bioscience Inc (DARE) secures significant funding and progresses with FDA interactions, despite facing increased ...

Daré will host a conference call and live webcast today, November 14, 2024, at 4:30 p.m. Eastern Time to review financial ...

Conference Call and Webcast Today at 4:30 p.m. ET Development Program Highlights and Anticipated Milestones Ovaprene® hormone-free monthly intravaginal contraceptive candidate - pivotal Phase 3 contra ...

She also notes that sarecycline has less effect on the gut than other oral antibiotics, such as clindamycin phosphate ... a doctor may prescribe a gel or cream called Tazorac.

Topical antibiotics available for treating acne include clindamycin (1% gel, lotion ... must have hematologic monitoring. A glucose-6-phosphate dehydrogenase level must be normal before beginning ...

FDA Approvals: Ziana, Kadian, Polyphenon E The FDA has approved clindamycin phosphate 1.2% plus tretinoin 0.025% gel (Ziana), an 80-mg dose strength for morphine sulfate extended-release capsules ...

Brian Kemp Dolliver; Analyst; Brookline Capital Markets Douglas Tsao; Analyst; H.C. Wainwright & Co LLC ...

XOMA Royalty recorded total income and revenues of $7.2 million for the third quarter of 2024, which included $6.5 million in estimated income associated with two commercial products in our portfolio.

This financial move aims to bolster Dare's development of its investigational products. The company's portfolio includes XACIATO (clindamycin phosphate) vaginal gel 2%, already FDA-approved and ...

the commercial assets in XOMA Royalty’s milestone and royalty portfolio are VABYSMO® (faricimab-svoa), OJEMDA™ (tovorafenib), MIPLYFFA™ (arimoclomol), XACIATO™ (clindamycin phosphate ...

Zevra’s MIPLYFFA™ (arimoclomol) received FDA approval and became the sixth commercial asset in XOMA Royalty’s portfolio XOMA Royalty acquired a 50 percent economic ...